Drug Innovation

Commentary

Empowering Frivolous Healthcare Litigation Does Not Help Patients

Of all the problems troubling the U.S. healthcare system, too little litigation is not one of them. And yet, the “Creating and Restoring Equal Access to Equivalent Samples Act of 2016” (CREATES Act), which is currently being rushed through Congress, takes just such an approach. If implemented, the CREATES Act ...
Commentary

Hillary’s Price Controls Would Kill New Drug Innovation

Like your iPhone? Federal officials designed it. Couldn’t live without the Internet? Thank Uncle Sam — he invented it. Sick and need new medicine? Don’t worry — the government is here to help. This fantastical line of thinking — that because the government funded basic, early-stage research, it can claim ...
Commentary

The Senate should reject foreign drug importation

Congress must send a budget to President Obama by next Friday. Senate lawmakers, hoping to avoid a government shutdown, have just started sparring over the details of their reconciliation measure. Sen. John McCain (R-Ariz.) has introduced an amendment to legalize the importation of certain prescription drugs from abroad. On the ...
Commentary

To Cure Rare Diseases, Unleash Orphan Drug Innovations

Last month, the City of Pittsburgh hosted the 35th annual Great Race, a charity run that raises money for the Richard S. Caliguiri Amyloidosis Research Fund. Caliguiri, a former Pittsburgh mayor, died of this rare protein disorder, and a portion of the race proceeds are used to help find a ...
Business & Economics

Putting Drug Research in Legal Jeopardy

The U.S. Supreme Court’s recent ruling in Wyeth v. Levine—holding that drug manufacturers are not free of liability under state law, even when the drug in question has secured federal regulatory approval—has worried pharmaceutical manufacturers, who can now face crippling state tort lawsuits despite being in regulatory compliance. A less-noticed ...
Commentary

Empowering Frivolous Healthcare Litigation Does Not Help Patients

Of all the problems troubling the U.S. healthcare system, too little litigation is not one of them. And yet, the “Creating and Restoring Equal Access to Equivalent Samples Act of 2016” (CREATES Act), which is currently being rushed through Congress, takes just such an approach. If implemented, the CREATES Act ...
Commentary

Hillary’s Price Controls Would Kill New Drug Innovation

Like your iPhone? Federal officials designed it. Couldn’t live without the Internet? Thank Uncle Sam — he invented it. Sick and need new medicine? Don’t worry — the government is here to help. This fantastical line of thinking — that because the government funded basic, early-stage research, it can claim ...
Commentary

The Senate should reject foreign drug importation

Congress must send a budget to President Obama by next Friday. Senate lawmakers, hoping to avoid a government shutdown, have just started sparring over the details of their reconciliation measure. Sen. John McCain (R-Ariz.) has introduced an amendment to legalize the importation of certain prescription drugs from abroad. On the ...
Commentary

To Cure Rare Diseases, Unleash Orphan Drug Innovations

Last month, the City of Pittsburgh hosted the 35th annual Great Race, a charity run that raises money for the Richard S. Caliguiri Amyloidosis Research Fund. Caliguiri, a former Pittsburgh mayor, died of this rare protein disorder, and a portion of the race proceeds are used to help find a ...
Business & Economics

Putting Drug Research in Legal Jeopardy

The U.S. Supreme Court’s recent ruling in Wyeth v. Levine—holding that drug manufacturers are not free of liability under state law, even when the drug in question has secured federal regulatory approval—has worried pharmaceutical manufacturers, who can now face crippling state tort lawsuits despite being in regulatory compliance. A less-noticed ...
Scroll to Top